Table 4.
Malaria treatment practices reported by populations
| Children < 5 years | 5–15 years | 16 years and above | Pregnant women | Total | p-value | |
|---|---|---|---|---|---|---|
| Frequency (%) | Frequency (%) | Frequency (%) | Frequency (%) | Frequency (%) | ||
| N | 462 | 460 | 438 | 34 | 1394 | |
| Malaria RDT test performed | ||||||
| Yes | 348 (75.3) | 334 (72.6) | 285 (65.1) | 24 (73.5) | 992 (71.2) | < 0.001 |
| No | 108 (23.4) | 126 (27.4) | 153 (34.9) | 9 (26.5) | 396 (28.4) | |
| Unknown | 6 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (0.4) | |
| Malaria test result | ||||||
| Positive | 326 (93.7) | 330 (98.8) | 280 (98.2) | 22 (88.0) | 958 (96.6) | < 0.001 |
| Negative | 4 (1.1) | 0 (0.0) | 3 (1.0) | 1 (4.0) | 8 (0.8) | |
| Unknown | 16 (4.6) | 4 (1.2) | 1 (0.4) | 2 (8.0) | 23 (2.3) | |
| Missing data | 2 (0.6) | 0 (0.0) | 1 (0.4) | 0 | 3 (0.3) | |
| Treatment receiveda | ||||||
| Malaria drug | ||||||
| ACT | 319 (71.8) | 350 (78.7) | 310(75.8) | 15(48.4) | 994 (74.8) | < 0.001 |
| Non-ACT drugb | 11 (2.5) | 11 (2.5) | 21 (5.1) | 5 (16.1) | 51 (03.8) | < 0.001 |
| Artemisinin monotherapyc | 15 (03.4) | 6 (1.4) | 7 (1.7) | 5 (16.1) | 33 (02.5) | < 0.001 |
| Non-Malaria drug | ||||||
| Antipyretics | 385 (86.7) | 410 (92.1) | 375 (91.7) | 25 (80.7) | 1195 (89.9) | 0.01 |
| Antibiotics | 60 (13.5) | 30 (6.7) | 20 (4.9) | 4 (12.9) | 114 (23.5) | < 0.001 |
| Unknown | 17 (03.8) | 8 (1.8) | 15 (3.7) | 2 (6.5) | 42 (3.2) | 0.31 |
| Name of ACT received | ||||||
| Artemether-lumefantrine | 313 (98.1) | 343 (98.3) | 304 (98.1) | 15 (100.0) | 975 (98.2) | 0.95 |
| Other ACTsd | 6 (1.9) | 6 (1.7) | 6 (1.9) | 0 (0.0) | 18 (1.8) | |
| Adherence of duration of treatment with ACT | ||||||
| 1–2 days | 25 (7.8) | 13 (3.7) | 6 (1.9) | 1 (6.7) | 45 (4.5) | 0.01 |
| 3 days | 244 (76.5) | 295 (84.5) | 279 (90.9) | 12 (80.0) | 830 (83.6) | |
| > 3 days | 47 (14.7) | 39 (11.2) | 22 (7.1) | 2 (13.3) | 110 (11.1) | |
| Missing information | 3 (0.9) | 2 (0.6) | 3 (1.0) | 0 | 8 (0.8) | |
aMultiple responses (percentages add to more than 100% as some patients had more than one reason of choosing a provider)
bQuinine, sulfadoxine-pyrimethamine
cArtesunate and artemether injectable
dPyronaridine-artesunate or amodiaquine-artesunate or dihydroartemisinin-piperaquine